why choose us

First received: March 14, 2025

Clinical Trial: BLAZE-Limiting Approach in NMOSD

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Neuromyelitis Optica Spectrum Disorders (NMOSD)

Study Type: OBSERVATIONAL


Official Title: Eculizumab for Blaze-limiting Approach in NMOSD: A Prospective Study

Brief Summary: This is an observational cohort study based on data from the hospital-based NMOSD registry (Chinese Medical Research Registration Number MR-31-22-008563; ChiCTR2000030651).Between October 2023 (when eculizumab was approved for NMOSD in China) and February 2025, 26 consecutive patients with AQP4-IgG-positive NMOSD received eculizumab, and 9 of them were included in this study.

Read more